Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone.

Tytuł :
Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone.
Autorzy :
Distaso E; Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124, Bari, Italy.
Milella G; Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124, Bari, Italy.
Mezzapesa DM; Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124, Bari, Italy.
Introna A; Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124, Bari, Italy.
D'Errico E; Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124, Bari, Italy.
Fraddosio A; Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124, Bari, Italy.
Zoccolella S; ASL Bari, San Paolo Hospital, Milano, Italy.
Dicuonzo F; Neuroradiology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70100, Bari, Italy.
Simone IL; Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124, Bari, Italy. .
Pokaż więcej
Źródło :
Journal of neurology [J Neurol] 2021 Sep; Vol. 268 (9), pp. 3307-3315. Date of Electronic Publication: 2021 Mar 02.
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Original Publication: Berlin ; New York, Springer-Verlag
MeSH Terms :
Amyotrophic Lateral Sclerosis*/diagnostic imaging
Amyotrophic Lateral Sclerosis*/drug therapy
Benchmarking ; Edaravone ; Humans ; Magnetic Resonance Imaging ; Magnetic Resonance Spectroscopy ; Pyramidal Tracts
References :
Neurobiol Aging. 2018 Feb;62:146-158. (PMID: 29149632)
J Neurol Neurosurg Psychiatry. 1960 Nov;23(4):269-82. (PMID: 21610893)
Neurology. 2010 Nov 2;75(18):1645-52. (PMID: 21041787)
J Neurol Sci. 1994 Jul;124 Suppl:96-107. (PMID: 7807156)
Neurology. 2006 Jan 24;66(2):265-7. (PMID: 16434671)
J Neurol. 2014 Oct;261(10):1871-80. (PMID: 25022938)
J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):53-5. (PMID: 18931009)
Neuroimage. 2018 May 1;171:6-14. (PMID: 29288131)
J Neurol. 2020 Nov;267(11):3258-3267. (PMID: 32556567)
Brain. 2011 Apr;134(Pt 4):1211-28. (PMID: 21362631)
Neuroimage. 2010 Dec;53(4):1181-96. (PMID: 20637289)
Brain. 2014 Sep;137(Pt 9):2546-55. (PMID: 24951638)
Lancet Neurol. 2017 Jul;16(7):505-512. (PMID: 28522181)
Neuroimage. 1999 Feb;9(2):250-68. (PMID: 9927554)
Front Neurosci. 2018 Oct 25;12:784. (PMID: 30410433)
Neurology. 2019 Sep 3;93(10):e984-e994. (PMID: 31409738)
Muscle Nerve. 2020 Feb;61(2):218-221. (PMID: 31621933)
Neuroimage. 2009 Jan 1;44(1):83-98. (PMID: 18501637)
Free Radic Biol Med. 2013 Dec;65:509-527. (PMID: 23797033)
Anesthesiology. 2012 Mar;116(3):603-12. (PMID: 22293721)
eNeurologicalSci. 2018 May 17;11:11-14. (PMID: 29928711)
J Neurol Sci. 1995 Dec;134(1-2):189-96. (PMID: 8747865)
Neuroimage. 2012 Jul 16;61(4):1402-18. (PMID: 22430496)
J Clin Neurol. 2014 Jul;10(3):249-56. (PMID: 25045379)
Neuroimage Clin. 2017 Aug 02;16:240-247. (PMID: 28794983)
J Thorac Cardiovasc Surg. 2007 Nov;134(5):1128-35. (PMID: 17976439)
BMC Neurosci. 2012 Nov 08;13:141. (PMID: 23134591)
PLoS One. 2013 Nov 20;8(11):e80748. (PMID: 24278317)
Neuroimage. 2006 Jul 15;31(4):1487-505. (PMID: 16624579)
Lancet Neurol. 2017 Oct;16(10):772. (PMID: 28920878)
BMC Neurol. 2016 Aug 27;16(1):155. (PMID: 27567641)
J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):917-924. (PMID: 28710326)
J Neurol Sci. 2019 Sep 15;404:47-51. (PMID: 31325668)
Muscle Nerve. 2020 Apr;61(4):508-511. (PMID: 31743477)
Hum Brain Mapp. 2020 Jun 15;41(9):2514-2526. (PMID: 32090440)
Hum Brain Mapp. 2013 Nov;34(11):3000-9. (PMID: 22807270)
Amyotroph Lateral Scler Frontotemporal Degener. 2019 May;20(3-4):260-263. (PMID: 30784320)
Neuroimage Clin. 2020;27:102315. (PMID: 32593977)
Sleep. 2017 Mar 01;40(3):. (PMID: 28364425)
Neurology. 1999 Sep 22;53(5):1051-8. (PMID: 10496265)
Neuroimage. 2009 Nov 1;48(2):371-80. (PMID: 19559801)
Neurotherapeutics. 2017 Jan;14(1):11-23. (PMID: 27752938)
Neuroimage. 2011 Jul 1;57(1):19-21. (PMID: 21376812)
Contributed Indexing :
Keywords: ALS; Cortical thickness; Edaravone; Fractional anisotropy; Longitudinal study; MRI
Substance Nomenclature :
S798V6YJRP (Edaravone)
Entry Date(s) :
Date Created: 20210303 Date Completed: 20210813 Latest Revision: 20210831
Update Code :
20220301
PubMed Central ID :
PMC8357666
DOI :
10.1007/s00415-021-10495-9
PMID :
33655342
Czasopismo naukowe
Background: Edaravone was approved as a new treatment for amyotrophic lateral sclerosis (ALS), although there are different opinions on its effectiveness. Magnetic resonance (MRI) measures appear promising as diagnostic and prognostic indicators of disease. However, published studies on MRI using to monitor treatment efficacy in ALS are lacking.
Purpose: The objective of this study was to investigate changes in brain MRI measures in patients treated with edaravone.
Methods: Thirteen ALS patients assuming edaravone (ALS-EDA) underwent MRI at baseline (T0) and after 6 months (T6) to measure cortical thickness (CT) and fractional anisotropy (FA) of white matter (WM) tracts. MRI data of ALS-EDA were compared at T0 with those of 12 control subjects (CS), and at T6 with those of 11 ALS patients assuming only riluzole (ALS-RIL), extracted from our ALS cohort using a propensity-score-matching. A longitudinal MRI analysis was performed in ALS-EDA between T6 and T0.
Results: At T0, ALS-EDA showed a cortical widespread thinning in both hemispheres, particularly in the bilateral precentral gyrus, and a reduction of FA in bilateral corticospinal tracts, in comparison to CS. Thinning in bilateral precentral cortex and significant widespread reduction of FA in several WM tracts were observed in ALS-EDA at T6 compared to T0. At T6, no significant differences in MRI measures of ALS-EDA versus ALS-RIL were found.
Conclusions: Patients treated with edaravone showed progression of damage in the motor cortex and several WM tracts, at a six-month follow-up. Moreover, this study showed no evidence of a difference between edaravone and riluzole.
(© 2021. The Author(s).)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies